COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

Phase 2 Trial of Intensive Chemo-immunotherapy with Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Relapsed/Refractory Myeloma in the Context of Salvage Autologous Hematopoietic Cell Transplantation

Protocol No
MSKCC-17-493
Principal Investigator
Saurabh Chhabra
Phase
II
Summary
The purpose of this study is to test any good and bad effects of giving a combination of study drugs before and after autologous stem cell transplant.
Description
A study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for patients with relapsed refractory Multiple Myeloma in the context of an autologous hematopoietic stem cell transplant
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL